Comparative Pharmacology
Head-to-head clinical analysis: LARIN FE 1 20 versus LO TROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN FE 1 20 versus LO TROL.
LARIN FE 1/20 vs LO-TROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LARIN FE 1/20 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets per cycle.
IV: 1-2 mg every 2-4 hours as needed; maximum 8 mg/24 hours.
None Documented
None Documented
Ethinyl estradiol: ~13 hours (range 7-20); norethindrone: ~8-11 hours. Steady-state reached in 5-7 days.
The terminal elimination half-life is 8.2 ± 1.5 hours in healthy adults. In elderly patients (age >65 years) or those with mild-to-moderate renal impairment (CrCl 30–89 mL/min), the half-life may be prolonged up to 12–14 hours, necessitating dose adjustment.
Renal (60% as metabolites, <10% unchanged); biliary/fecal (40%)
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with an additional 25% recovered as glucuronide conjugates in urine. Biliary/fecal excretion represents about 15% of total clearance.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive